Company intelligence / Profile preview
Race Oncology
Australiaraceoncology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Race Oncology is advancing RC220 (bisantrene), a reformulated version of a previously approved chemotherapeutic. The company has completed two Phase 2 trials in relapsed/refractory AML showing 40% response rates. Currently conducting a Phase 1 trial of RC220 in combination with doxorubicin for solid tumors, with the first patient safely dosed in Q2 2025. Preclinical studies show bisantrene may protect the heart from anthracycline-induced damage while providing additional anticancer activity.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesChemotherapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sheba Medical Center (Israel)City of Hope (Los Angeles)
Beyond the preview
Go deeper on Race Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Race Oncology.